2--3--o-(2-4-6-trinitrophenyl)adenosine-5--triphosphate and Hyperplasia

2--3--o-(2-4-6-trinitrophenyl)adenosine-5--triphosphate has been researched along with Hyperplasia* in 1 studies

Other Studies

1 other study(ies) available for 2--3--o-(2-4-6-trinitrophenyl)adenosine-5--triphosphate and Hyperplasia

ArticleYear
P2X purinergic receptor antagonist accelerates skin barrier repair and prevents epidermal hyperplasia induced by skin barrier disruption.
    The Journal of investigative dermatology, 2002, Volume: 119, Issue:5

    The effects of ATP receptor agonists/antagonists on skin barrier recovery rate were evaluated in hairless mice. Topical application of ATP and alpha,beta-methylene ATP (agonist of P2X receptor) delayed barrier recovery. Topical application of suramin (nonspecific ATP receptor antagonist), pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) (P2X receptor antagonist), and 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP) (P2X1, P2X3, P2X2/3 antagonist) after barrier disruption accelerated the barrier repair. The P2Y type receptor antagonist Reactive Blue 2 did not affect the barrier repair process. Moreover, topical application of TNP-ATP prevented epidermal hyperplasia induced by barrier insult under low environmental humidity. ATP was secreted immediately after tape stripping on skin in organ culture. alpha,beta-Methylene ATP increased intercellular calcium in cultured keratinocytes and the increase was blocked by TNP-ATP. Both reverse transcription polymerase chain reaction assay and immunohistochemical study showed the existence of protein that had a structure similar to P2X3 on hairless mouse epidermis. These results suggest that cutaneous barrier homeostasis can be regulated by cation flux through a P2X3-like ATP receptor.

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Calcium; Cells, Cultured; Epidermis; Fluorescent Dyes; Hyperplasia; Immunohistochemistry; Keratinocytes; Male; Mice; Mice, Hairless; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Pyridoxal Phosphate; Reverse Transcriptase Polymerase Chain Reaction; Suramin; Water; Wound Healing

2002